Known targets — ChEMBL curated mechanism
ABL1BMXBRAFBTKCHRNA4CHRNB2CSNK1EEGFRERBB2F10FLT1FLT3FLT4IGF1RINSRITKJAK3KDRKITOPRM1PARP1PARP2PDGFRBPIK3CDRAF1RETSLC18A2TECTXKdacAdacBdacCftsImrcAmrcBmrdArplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Resminostat. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 17/20 | 0.85 |
| ▸ | HDAC6 | Q9UBN7 | 13/20 | 0.85 |
| ▸ | HDAC3 | O15379 | 6/20 | 0.83 |
| ▸ | HDAC8 | Q9BY41 | 4/20 | 0.83 |
| ▸ | HDAC2 | Q92769 | 11/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | HDAC4 | P56524 | 5/20 | 0.44 |
| ▸ | MEF2D | Q14814 | 1/20 | 0.43 |
| ▸ | HDAC10 | Q969S8 | 3/20 | 0.41 |
| ▸ | HDAC11 | Q96DB2 | 3/20 | 0.41 |
| ▸ | HDAC9 | Q9UKV0 | 3/20 | 0.41 |
| ▸ | HDAC7 | Q8WUI4 | 2/20 | 0.41 |
| ▸ | HDAC5 | Q9UQL6 | 2/20 | 0.41 |
| ▸ | KDM1A | O60341 | 1/20 | 0.40 |
| ▸ | BRD4 | O60885 | 1/20 | 0.40 |
| ▸ | BRD2 | P25440 | 1/20 | 0.40 |
| ▸ | BRD3 | Q15059 | 1/20 | 0.40 |
| ▸ | BRD7 | Q9NPI1 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Resminostat SCHEMBL299941 | 1.00 | HDAC1 (0.85) | HDAC1HDAC6HDAC3HDAC8HDAC2 | |
| Resminostat SCHEMBL299945 | 0.92 | HDAC1 (0.85) | HDAC1HDAC6HDAC3HDAC8HDAC2 | |
| Resminostat SCHEMBL299947 | 0.92 | HDAC1 (0.85) | HDAC1HDAC6HDAC3HDAC8HDAC2 | |
| Resminostat SCHEMBL299845 | 0.92 | HDAC1 (0.96) | HDAC1HDAC6HDAC3HDAC8HDAC2 | |
| Resminostat SCHEMBL299843 | 0.92 | HDAC1 (0.96) | HDAC1HDAC6HDAC3HDAC8HDAC2 | |
| Resminostat SCHEMBL295541 | 0.92 | HDAC1 (1.00) | HDAC1HDAC6HDAC3HDAC8HDAC2 | |
| Resminostat SCHEMBL295540 | 0.92 | HDAC1 (1.00) | HDAC1HDAC6HDAC3HDAC8HDAC2 | |
| Resminostat SCHEMBL1887878 | 0.91 | HDAC1 (1.00) | HDAC1HDAC6HDAC3HDAC8HDAC2 | |
| Resminostat SCHEMBL1887874 | 0.91 | HDAC1 (1.00) | HDAC1HDAC6HDAC3HDAC8HDAC2 | |
| Resminostat SCHEMBL299781 | 0.90 | HDAC1 (0.92) | HDAC1HDAC6HDAC3HDAC8HDAC2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8232297-B2 | Sulphonylpyrroles as inhibitors of HDACs novel sulphonylpyrroles | 4SC AG (DE) | 2012-07-31 | — | — | US | disclosed |
| EP-1928872-B1 | NOVEL SULPHONYLPYRROLES AS INHIBITORS OF HDAC | 4SC AG (DE) | 2012-03-14 | — | — | EP | disclosed |
| US-20090263353-A1 | Novel Sulphonylpyrroles as Inhibitors of Hdac S Novel Sulphonylpyrroles | NYCOMED GMBH (DE) | 2009-10-22 | — | — | US | disclosed |
| EP-1928872-A1 | NOVEL SULPHONYLPYRROLES AS INHIBITORS OF HDAC S NOVEL SULPHONYLPYRROLES | Nycomed GmbH (DE) | 2008-06-11 | — | — | EP | disclosed |
| WO-2007039404-A1 | NOVEL SULPHONYLPYRROLES AS INHIBITORS OF HDAC S NOVEL SULPHONYLPYRROLES | NYCOMED GMBH (DE) | 2007-04-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090263353-A1 | Novel Sulphonylpyrroles as Inhibitors of Hdac S Novel Sulphonylpyrroles | HDAC1, HDAC3, HDAC2 | HDAC1 1/4885HDAC6 8/4885HDAC3 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.